Kidney Cancer

AVEO Oncology recently announced that it has received a complete response letter from the FDA informing the company that the FDA will not approve in its present form the new drug application for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.

Physicians and patients alike may not be aware of the benefits of nephron-sparing surgical methods, according to a recent study.

Researchers at UCLA’s Institute of Urologic Oncology and department of urology have classified kidney cancer into several unique subtypes, a finding that could help physicians tailor treatment to individual patients.

A recently published population-based study reinforces prior evidence from retrospective studies of the increased survival benefit of partial nephrectomy over radical nephrectomy, and suggests a cancer-specific survival benefit for nephron-sparing approaches as well.

A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study.

Use of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase III clinical trial.

To optimize outcomes for patients with advanced renal cell carcinoma, multimodal therapy is often required.

A large retrospective study of older patients diagnosed with small kidney tumors showed that patients who undergo surgery to remove these tumors have the same risk of dying of kidney cancer over a 5-year period as those who undergo surveillance.